COMPANY PROFILE

Aerska

Explore full profile

RNAi medicines for treating neurological brain diseases

Dublin, IrelandFounded 2025Biotech & Life Sciences

Valuation $100–250M Last recorded · 2026

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Aerska

Aerska is a Dublin-headquartered biotechnology company founded in 2025 that develops RNA interference (RNAi) medicines for neurological diseases, with research operations in London. The company focuses on overcoming delivery into the central nervous system by pairing next-generation RNAi payloads with receptor-targeted ‘brain shuttle’ approaches intended to carry genetic medicines across the blood–brain barrier more effectively than conventional modalities. Its pipeline targets neurodegenerative and related CNS indications where durable gene silencing could slow or prevent disease progression. In 2026 Aerska raised a €32 million Series A led by EQT Dementia Fund and age1 to advance its RNA platform and move neurological programmes toward clinical development. The round positions the company among Europe’s better-funded early CNS genetic-medicine ventures and funds platform R&D, delivery chemistry, and team growth across Ireland and the UK.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2025
Headquarters: Dublin, Ireland
Employees: 24
Open positions: 1
Dealroom signal: 60.4/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Medical Research, Medical & Healthcare, RNA, Biotech and Pharma, Cell Therapy, Techbio Drug Discovery
Business model: Manufacturing
Client focus: b2c
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	May 2026	$10M	$195M	Global Health Investment Corporation	↗
SERIES AOther financing	Feb 2026	$39M	$156M	Iaso Ventures · EQT Life Sciences · Age1	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Aerska website traffic

Latest recorded traffic for Aerska is 1.3K monthly website visits, up 18.2% over the last three months.

Latest monthly visits1.3K 3-month web change+18.2%

Monthly website visitsOct 2025–May 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
MOMoleculeaiAI driven drug-discovery platform that uses deep learning and generative modeling to radically shorten the time and cost of discovering new therapeutic molecules	New Delhi, India	Acquired	9	—	—
GEGenicityDeveloping on-the-shelf therapies for solid and liquid tumors using allogenic T-cell receptor therapies	Galway, Ireland	Operational
RBReThink64 BionetworksIntercellular router system for large-molecule drug delivery	Fremont, United States	Operational
ABAptuCure BioDeveloping AptuBodies, unique revolutionary synthetic aptamer-based nanoparticles mimicking antibody activity	Rehovot, Israel	Operational
ABAvenue BiosciencesInnovative protein engineering solutions integrating biologics and machine learning for therapeutic advancements	Palo Alto, United States	Operational
OLOlden LabsInnovative solutions for optimizing Apache2 server configurations on Ubuntu systems	San Francisco, United States	Operational
SBStemX BioInnovative 3D microtissue models for drug discovery and regenerative medicine research	Leiden, Netherlands	Operational
PTPasskey TherapeuticsDiscovering new medicines by unlocking rational polypharmacology	Cambridge, United States	Operational